FDA Clears AVAVA's Focal Point Technology for Acne Scar Treatment Across All Skin Types
• AVAVA's non-ablative Focal Point Technology has received FDA clearance for treating acne scars in all Fitzpatrick skin types (I-VI), addressing a significant gap in treatment options for patients with darker skin tones.
• Clinical trials demonstrated over 90% of subjects experienced visible improvement in acne scarring with a median 50% reduction in scar severity, with 75% of participants identifying as African American, Asian, or Hispanic/Latino.
• The technology delivers high-energy treatments (up to 150mJ) while sparing surrounding tissue, resulting in minimal downtime with side effects like mild redness and swelling typically resolving within 1-2 days.
© Copyright 2025. All Rights Reserved by MedPath